Our RESETTM clinical trials with CABA-201 (investigational CD19-CAR T cell therapy) in lupus, myositis, systemic sclerosis, myasthenia gravis, and pemphigus vulgaris are now recruiting.
| Date | Form | Description | XBRL | Pages | |
|---|---|---|---|---|---|
| 11/06/23 | 8-K | Current report filing |
|
   |
7 |
| 10/19/23 | 4 | Statement of changes in beneficial ownership of securities |
|
1 | |
| 10/19/23 | 144 | Filing for proposed sale of securities under Rule 144 |
|
3 | |
| 10/02/23 | 8-K | Current report filing |
|
|
32 |
| 09/20/23 | 4 | Statement of changes in beneficial ownership of securities |
|
1 | |
| 09/19/23 | 144 | Filing for proposed sale of securities under Rule 144 |
|
3 | |
| 09/05/23 | 8-K | Current report filing |
|
|
27 |
| 08/22/23 | 4 | Statement of changes in beneficial ownership of securities |
|
1 | |
| 08/22/23 | 8-K | Current report filing |
|
|
6 |
| 08/21/23 | 144 | Filing for proposed sale of securities under Rule 144 |
|
3 |
